Nkarta (NKTX)
NASDAQ:NKTX
Top Page
Nkarta
(NASDAQ:NKTX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.00
▼(-2.91% Downside)
Action:ReiteratedDate:03/26/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and significant cash burn), with additional pressure from bearish technical indicators. Valuation provides limited support because negative earnings make P/E less informative and there is no dividend yield.
Positive Factors
Off-the-shelf CAR‑NK platform
Nkarta's allogeneic, off-the-shelf NK cell platform is inherently scalable versus autologous approaches, supporting manufacturing efficiency and broader patient access. A platform that targets receptor/ligand biology across hematologic malignancies can enable multiple indications and durable enterprise value if clinical proof emerges.
Negative Factors
High cash burn and negative FCF
Sustained negative operating and free cash flow near -$90M annually creates structural funding pressure. Until revenues or durable partnership milestones emerge, the company must rely on external capital, which tightens runway and constrains long‑term investment choices if burn remains elevated.
Read all positive and negative factors
Positive Factors
Negative Factors
Off-the-shelf CAR‑NK platform
Nkarta's allogeneic, off-the-shelf NK cell platform is inherently scalable versus autologous approaches, supporting manufacturing efficiency and broader patient access. A platform that targets receptor/ligand biology across hematologic malignancies can enable multiple indications and durable enterprise value if clinical proof emerges.
Read all positive factors
Nkarta (NKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$146.86M
Dividend YieldN/A
Average Volume (3M)673.55K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue GrowthN/A
EPS Growth25.84%
CountryUS
Employees157
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.37
Shares Outstanding71,290,490
10 Day Avg. Volume604,631
30 Day Avg. Volume673,551
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-81.37
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$12.67Price Target Upside515.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Nkarta Business Overview & Revenue Model
Company Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (...
How the Company Makes Money
Nkarta is a clinical-stage biotech and, based on publicly available information at this stage of development, it has not consistently generated recurring revenue from product sales; its funding has historically been primarily driven by financing a...
Nkarta Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.19M | 0.00 | -5.87M | 0.00 | 0.00 |
| EBITDA | -112.01M | -119.04M | -120.48M | -116.32M | -84.67M |
| Net Income | -104.08M | -108.79M | -117.50M | -113.84M | -86.08M |
Balance Sheet | |||||
| Total Assets | 404.21M | 501.20M | 378.88M | 472.94M | 273.90M |
| Cash, Cash Equivalents and Short-Term Investments | 276.28M | 267.35M | 248.19M | 352.14M | 238.09M |
| Total Debt | 76.42M | 80.27M | 88.34M | 82.93M | 12.46M |
| Total Liabilities | 91.88M | 93.23M | 105.60M | 100.73M | 22.94M |
| Stockholders Equity | 312.32M | 407.98M | 273.29M | 372.21M | 250.97M |
Cash Flow | |||||
| Free Cash Flow | -89.91M | -104.11M | -114.31M | -104.11M | -72.95M |
| Operating Cash Flow | -88.70M | -99.70M | -86.16M | -57.00M | -67.93M |
| Investing Cash Flow | 100.32M | -129.56M | 79.02M | -184.69M | 32.53M |
| Financing Cash Flow | 141.00K | 226.08M | 691.00K | 219.01M | 1.20M |
Nkarta Technical Analysis
Negative
2.06
Price Trends
2.28
Negative
2.08
Negative
2.08
Negative
Market Momentum
-0.06
Positive
39.33
Neutral
23.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NKTX, the sentiment is Negative. The current price of 2.06 is below the 20-day moving average (MA) of 2.34, below the 50-day MA of 2.28, and below the 200-day MA of 2.08, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 39.33 is Neutral, neither overbought nor oversold. The STOCH value of 23.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NKTX.
Nkarta Risk Analysis
Nkarta disclosed 78 risk factors in its most recent earnings report. Nkarta reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nkarta Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $192.89M | 4.04 | 55.68% | ― | -88.47% | -1658.33% | |
52 Neutral | $235.16M | -1.51 | -53.83% | ― | -10.57% | 1.98% | |
52 Neutral | $198.16M | -6.23 | -131.80% | ― | ― | -16.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $430.82M | -7.52 | -65.03% | ― | -84.46% | 33.32% | |
44 Neutral | $146.86M | -1.25 | -30.02% | ― | ― | 25.84% | |
41 Neutral | $17.67M | -6.72 | 389.21% | ― | ― | -234.46% |
* Healthcare Sector Average
NKTX
Nkarta
2.06
0.06
3.00%
CGEN
Compugen
2.04
0.51
33.33%
CCCC
C4 Therapeutics
2.41
0.66
37.71%
STTK
Shattuck Labs
6.02
4.96
467.92%
TVGN
Tevogen Bio Holdings
4.37
-55.64
-92.73%
NVCT
Nuvectis Pharma
7.48
-2.98
-28.49%
Nkarta Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Nkarta Launches $100 Million At-the-Market Stock Offering
Neutral
Mar 26, 2026
On March 25, 2026, Nkarta, Inc. entered into a Sales Agreement with Stifel, Nicolaus Company for an at-the-market equity offering of up to $100 million of its common stock, with Stifel acting as sales agent and earning a commission of up to 3% on...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.